Tissera, Inc. (OTCBB:TSSRE - News) reports that Prof. Yair Reisner, Director of Tissera's sponsored research at the Weizmann Institute of Science and Chairman of the company's Advisory Scientific Board, has been awarded the prestigious Abish-Frenkel Prize for Excellence in the Life Sciences at the International Stem Cell Symposium, held at the Weizmann Institute on November 28-29, 2004.

As part of the Prize Lecture given by Prof. Reisner at the Symposium, he presented new data demonstrating the efficacy of transplanted porcine fetal pancreatic tissue, harvested within a defined specific gestational time window, in achieving cure of diabetic mice.

Prof. Reisner further indicated that he intends to implement this approach in large animal models, in collaboration with the Transplantation Division of the Department of Surgery of the University of Minnesota.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera obtained the license for the worldwide exclusive rights to the technology developed by Professor Yair Reisner and his team at the Weizmann Institute of Science in Israel. In this research, scientists successfully implanted in mice embryonic human and porcine organ precursor tissues, which grew into functional organs. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Such statements, including statements regarding freedom to operate, patentability, infringement, clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."
 

---

Contact:

     Tissera, Inc.
     (Investor Relations)
     Dr. Uri Elmaleh, 972-54-2223344
     uri@tissera.com